Growth hormone (GH) is produced by somatotropes of the anterior pituitary gland and is released into the general circulation where it stimulates the production of insulin-like growth factor I (IGF-I) from multiple target tissues. GH and IGF-I work in concert to mediate various aspect of cellular function. In normal individuals, circulating GH/IGF-I levels steadily rise after to birth, plateau around the peripubertal period, then decline thereafter at a rate of ~14% for every decade of life. Circulating GH levels also decline with weight gain, independent of age. Based on human and animal studies examining the metabolic impact of GH deficiency (GHD), with and without GH or IGF-I replacement, it is clear that GH can inhibit fat accumulation and promote protein accretion, while the metabolic actions of IGF-I resemble those of insulin. GH and IGF-I are also reported to have positive effects on pancreatic b-cell function, cardiovascular performance and bone remodeling. The metabolic benefits of GH replacement in GHD patients has fueled the off-label use and abuse of GH in normal healthy adults to enhance body image and athletic performance, as well as providing a rationale for GH replacement in elderly and/or obese individuals to help combat metabolic disease. Despite the potential positive effects of GH in adults, there is also ongoing debate whether GH, at physiologic levels, can reduce insulin sensitivity, exacerbate cancer, and shorten lifespan. The true importance of endogenous GH in maintaining health OR promoting disease in adults, remains to be clarified since the bulk of our knowledge is based on studies of 1 ) acute or long-term GH administration in normal subjects, 1) developmental GHD, that might not reflect the consequences of GH decline after sexual maturation and 2) adult onset GHD (AOGHD) which is frequently accompanied by other pituitary defects, making it difficult to determine what changes are due specifically to GH loss. In addition, in humans it is difficult to separate out the confounding effects of genetics, environment and lifestyle from those due specifically to endocrine pathologies. To circumvent these problems and more accurately define the importance of endogenous GH in adult (patho)physiology the current proposal will utilize a unique genetically engineered mouse model of adult-onset, isolated GHD (AOiGHD). Preliminary studies demonstrated when AOiGHD mice were fed a low-fat diet, adipose mass increased, but whole body insulin sensitivity improved. However, diet-induced obese AOiGHD mice developed glucose intolerance which was associated with low fed and fasted insulin levels, suggesting GH/IGF-I may also be important in maintaining b-cell function. Given multiple organs systems are involved in maintaining glucose homeostasis, the proposed series of studies will take an integrative approach to determine 1) at what level AOiGHD impacts b-cell function (insulin expression, proliferation, neogenesis and/or apoptosis), 2) if the AOiGHD-induced increase in insulin sensitivity is due to global improvement in insulin actions or due to tissue-specific changes (liver, fat, skeletal muscle) 3) determine if AOiGHD will influence whole body metabolism and weight changes in response to acute fasting/refeeding or longterm diet-induced weight loss. Knowledge gained from these studies will provide important information regarding the benefits or risks of GH replacement therapy.

Public Health Relevance

Project Narrative Relevant to our modern society is determining if the normal fall in growth hormone (GH) that occurs with weight gain and age, is a major contributor to the deterioration of metabolic function. This proposal will utilize a novel mouse model of adult-onset, isolated GH deficiency (AOiGHD) to identify the key components of the metabolic homeostatic system that are most profoundly affected by selective reduction in circulating GH and IGF-I, in the context of sex, diet and nutrient availability. Information gained can be used in future experiments to determine if GH acts directly or indirectly on specific tissues/cells to mediate these effects.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project (R01)
Project #
Application #
Study Section
Integrative and Clinical Endocrinology and Reproduction Study Section (ICER)
Program Officer
Malozowski, Saul N
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Illinois at Chicago
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Luque, Raúl M; Córdoba-Chacón, José; Ibáñez-Costa, Alejandro et al. (2014) Obestatin plays an opposite role in the regulation of pituitary somatotrope and corticotrope function in female primates and male/female mice. Endocrinology 155:1407-17
Cordoba-Chacon, Jose; Gahete, Manuel D; Pokala, Naveen K et al. (2014) Long- but not short-term adult-onset, isolated GH deficiency in male mice leads to deterioration of ?-cell function, which cannot be accounted for by changes in ?-cell mass. Endocrinology 155:726-35
Gahete, Manuel D; Córdoba-Chacón, José; Lantvit, Daniel D et al. (2014) Elevated GH/IGF-I promotes mammary tumors in high-fat, but not low-fat, fed mice. Carcinogenesis 35:2467-73
Lubbers, Ellen R; List, Edward O; Jara, Adam et al. (2013) Adiponectin in mice with altered GH action: links to insulin sensitivity and longevity? J Endocrinol 216:363-74
Gahete, Manuel D; Cordoba-Chacon, Jose; Lin, Qing et al. (2013) Insulin and IGF-I inhibit GH synthesis and release in vitro and in vivo by separate mechanisms. Endocrinology 154:2410-20
Gahete, Manuel D; Cordoba-Chacon, Jose; Luque, Raul M et al. (2013) The rise in growth hormone during starvation does not serve to maintain glucose levels or lean mass but is required for appropriate adipose tissue response in female mice. Endocrinology 154:263-9
Cordoba-Chacon, Jose; Gahete, Manuel D; Pozo-Salas, Ana I et al. (2013) Endogenous somatostatin is critical in regulating the acute effects of L-arginine on growth hormone and insulin release in mice. Endocrinology 154:2393-8
Córdoba-Chacón, J; Gahete, M D; Culler, M D et al. (2012) Somatostatin dramatically stimulates growth hormone release from primate somatotrophs acting at low doses via somatostatin receptor 5 and cyclic AMP. J Neuroendocrinol 24:453-63
Cordoba-Chacon, Jose; Gahete, Manuel D; Castano, Justo P et al. (2012) Homologous and heterologous in vitro regulation of pituitary receptors for somatostatin, growth hormone (GH)-releasing hormone, and ghrelin in a nonhuman primate (Papio anubis). Endocrinology 153:264-72
Cordoba-Chacon, Jose; Gahete, Manuel D; Castano, Justo P et al. (2011) Somatostatin and its receptors contribute in a tissue-specific manner to the sex-dependent metabolic (fed/fasting) control of growth hormone axis in mice. Am J Physiol Endocrinol Metab 300:E46-54

Showing the most recent 10 out of 12 publications